Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Trial of AMG 386 and Temsirolimus in Advanced Solid Tumors With an Expansion Cohort in Uterine Cancer, Renal Cell Carcinoma and Carcinoid Tumors

Next Previous
Trial Profile

A Phase I Trial of AMG 386 and Temsirolimus in Advanced Solid Tumors With an Expansion Cohort in Uterine Cancer, Renal Cell Carcinoma and Carcinoid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 26 Dec 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trebananib (Primary) ; Temsirolimus
  • Indications Carcinoid tumour; Renal cell carcinoma; Solid tumours; Uterine cancer
  • Focus Adverse reactions

Most Recent Events

  • 19 Dec 2015 Results published in the Investigational New Drugs
  • 05 Oct 2015 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
  • 02 Mar 2015 Planned primary completion date changed from 1 Feb 2015 to 1 Sep 2015, as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top